Cannabics Pharmaceuticals Inc
CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug… Read more
Cannabics Pharmaceuticals Inc (CNBX) - Net Assets
Latest net assets as of November 2025: $-2.57 Million USD
Based on the latest financial reports, Cannabics Pharmaceuticals Inc (CNBX) has net assets worth $-2.57 Million USD as of November 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.16K) and total liabilities ($2.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.57 Million |
| % of Total Assets | -23051.16% |
| Annual Growth Rate | N/A |
| 5-Year Change | -238.23% |
| 10-Year Change | N/A |
| Growth Volatility | 202.32 |
Cannabics Pharmaceuticals Inc - Net Assets Trend (2005–2025)
This chart illustrates how Cannabics Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cannabics Pharmaceuticals Inc (2005–2025)
The table below shows the annual net assets of Cannabics Pharmaceuticals Inc from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-08-31 | $-2.50 Million | -0.66% |
| 2024-08-31 | $-2.48 Million | -22.94% |
| 2023-08-31 | $-2.02 Million | -23.58% |
| 2022-08-31 | $-1.63 Million | -190.39% |
| 2021-08-31 | $1.81 Million | +2.35% |
| 2020-08-31 | $1.76 Million | -88.03% |
| 2019-08-31 | $14.74 Million | +457.33% |
| 2018-08-31 | $2.65 Million | -9.97% |
| 2017-08-31 | $2.94 Million | +728.65% |
| 2016-08-31 | $-467.45K | -50.97% |
| 2015-08-31 | $-309.63K | -106.96% |
| 2014-08-31 | $4.45 Million | +4322.27% |
| 2013-08-31 | $-105.39K | -275.74% |
| 2010-08-31 | $59.97K | +134.28% |
| 2009-08-31 | $-174.95K | -160.35% |
| 2008-08-31 | $289.87K | +100.67% |
| 2006-08-31 | $144.45K | +11393.98% |
| 2005-08-31 | $-1.28K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cannabics Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2526657600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $55.40K | % |
| Other Components | $22.72 Million | % |
| Total Equity | $-2.50 Million | 100.00% |
Cannabics Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Cannabics Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anglesey Mining plc
F:4A0
|
$87.09K |
|
Upper Egypt Flour Mills
EGX:UEFM
|
$87.10K |
|
SASOL (SAOA.SG)
STU:SAOA
|
$87.11K |
|
Qlosr Group AB Series B
ST:QLOSR-B
|
$87.16K |
|
Archos
PA:ALJXR
|
$87.06K |
|
RABA (RMV1.SG)
STU:RMV1
|
$87.05K |
|
Four Arrows Capital Corp
V:AROW-P
|
$87.02K |
|
Iljin Diamond Co. Ltd.
KQ:081000
|
$86.93K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cannabics Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -2,479,980 to -2,496,293, a change of -16,313.
- Net loss of 313,976 reduced equity.
- Other factors increased equity by 297,663.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-313.98K | -12.58% |
| Other Changes | $297.66K | +11.92% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Cannabics Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-08-31 | $0.00 | $0.01 | x |
| 2006-08-31 | $17.33 | $0.01 | x |
| 2007-08-31 | $27.99 | $0.01 | x |
| 2008-08-31 | $25.57 | $0.01 | x |
| 2009-08-31 | $-15.43 | $0.01 | x |
| 2010-08-31 | $5.29 | $0.01 | x |
| 2011-08-31 | $-4.18 | $0.01 | x |
| 2012-08-31 | $-4.32 | $0.01 | x |
| 2013-08-31 | $-9.30 | $0.01 | x |
| 2014-08-31 | $5.33 | $0.01 | x |
| 2015-08-31 | $-0.37 | $0.01 | x |
| 2016-08-31 | $-0.54 | $0.01 | x |
| 2017-08-31 | $3.19 | $0.01 | x |
| 2018-08-31 | $2.64 | $0.01 | x |
| 2019-08-31 | $13.36 | $0.01 | x |
| 2020-08-31 | $1.57 | $0.01 | x |
| 2021-08-31 | $1.56 | $0.01 | x |
| 2022-08-31 | $-1.33 | $0.01 | x |
| 2023-08-31 | $-0.23 | $0.01 | x |
| 2024-08-31 | $-0.08 | $0.01 | x |
| 2025-08-31 | $-0.03 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cannabics Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-49.02%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.67K |
| 2006 | -13.86% | 0.00% | 0.00x | 1.19x | $-34.47K |
| 2007 | -7.31% | 0.00% | 0.00x | 1.00x | $-54.94K |
| 2008 | -9.47% | 0.00% | 0.00x | 1.01x | $-56.45K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-97.43K |
| 2010 | -191.73% | 0.00% | 0.00x | 1.58x | $-120.98K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-102.58K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $3.25K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-45.86K |
| 2014 | -6.07% | 0.00% | 0.00x | 1.02x | $-715.00K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-510.42K |
| 2016 | 0.00% | -272.89% | 4.74x | 0.00x | $-260.26K |
| 2017 | -65.81% | -34022.54% | 0.00x | 1.24x | $-2.23 Million |
| 2018 | -142.76% | -39335.66% | 0.00x | 1.20x | $-4.04 Million |
| 2019 | 7.68% | 11510.72% | 0.00x | 1.03x | $-341.43K |
| 2020 | -423.17% | -104331.42% | 0.00x | 1.26x | $-7.64 Million |
| 2021 | -176.86% | 0.00% | 0.00x | 1.70x | $-3.37 Million |
| 2022 | 0.00% | -12427.40% | 0.04x | 0.00x | $-3.56 Million |
| 2023 | 0.00% | -904.51% | 0.82x | 0.00x | $-3.51 Million |
| 2024 | 0.00% | -534.31% | 4.14x | 0.00x | $-447.00K |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-64.35K |
Industry Comparison
This section compares Cannabics Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cannabics Pharmaceuticals Inc (CNBX) | $-2.57 Million | 0.00% | N/A | $87.08K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |